In certain embodiments, a composition comprises aldesleukin in a pharmaceutical suitable aqueous vehicle, for parenteral administration to a patient in need of IL 2 immunotherapy, in which the aldesleukin has been prepared using the production method of the disclosure that ensures that the aldesleukin is stable in a pharmaceutical liquid composition for at least a year
stromectol company 2016; 13 5045 52 pubmed publisher